Loading
companiesCompany
Citius Pharmaceuticals
Citius Pharmaceuticals brought denileukin diftitox back to market as Lymphir, approved in 2024 for relapsed cutaneous T-cell lymphoma, through its Citius Oncology subsidiary.
Overview
Citius Pharmaceuticals, based in Cranford, New Jersey, and listed as CTXR, brought denileukin diftitox back to market as Lymphir, approved in 2024 for relapsed cutaneous T-cell lymphoma, through its Citius Oncology subsidiary. It licensed the reformulated denileukin diftitox, known as E7777, from Eisai in 2021 and secured FDA approval in August 2024 for adults with relapsed or refractory stage I to III cutaneous T-cell lymphoma after at least one systemic therapy. OnCo links it to the denileukin diftitox drug record. Whether a revived fusion toxin finds a stable place among the newer options for a rare lymphoma is the open question. Denileukin diftitox has its own page.
Headquarters
Cranford, New Jersey, US
Scorecard
All companies#228of 1244 companies, score 23
- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +12
1 approved, 0 in phase 3, 0 earlier, 1 targets, 35 registry studies. Formula on the scorecards page.
Type
Biotech · CTXR
Stage
Public
Website
ApprovedIL-2 receptor-directed cytotoxin (fusion protein)
Denileukin diftitox · Lymphir
Denileukin diftitox (Lymphir) is an infusion that uses the interleukin-2 signal as a homing device to deliver a bacterial toxin into cutaneous T-cell lymphoma cells. It was withdrawn in 2014 and returned in an improved form in 2024.
Similar pages
drugs
ApprovedIL-2 receptor-directed cytotoxin (fusion protein)
Denileukin diftitox · Lymphir